BridgeMD
A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors
EU CTIS ID: 2025-524623-50-00
What this study is testing
To evaluate the safety and tolerability of RAS(ON) inhibitors in combination with ivonescimab in patients with advanced RAS-mutated solid tumors To define the RP2D for RAS(ON) inhibitors in combination with ivonescimab, with or without other anti-cancer agents, in patients with advanced RAS-mutated solid tumors
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants may be included in the study if they • are at least 18 years old. • have a RAS-mutated cancer that has spread or cannot be removed by surgery and at least one tumor that can be measured by scans. Some parts of the study are only open to participants with a specific RAS mutation type. • have adequate organ function.
You likely can't join if
- Participants cannot be included in the study if they • have previously received certain medicines that directly target RAS, or certain immune or anti-VEGF therapies (cancer treatment that stops tumors from growing new blood vessels). • have any medical condition including a bleeding issue, or active infections that may interfere with the study medicine. • are pregnant or breastfeeding. • depending on the part of the study, participants may or may not have received previous treatment for their cancer.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.